Abstract: A DNA construct is disclosed which encodes a fusion protein comprising an amino acid sequence of a blood clotting factor like Factor IX and an amino acid sequence of the cytoplasmic domain of P-Selectin. Such construct may be used for the somatic gene therapy of patients suffering from a defiency of a blood coagulation factor.

Abstract: A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.

Abstract: A process and an agent for the sanitization of tissues or cell cultures and also of materials and equipment which can be contaminated with viruses are described. For sanitization, a solution of a substituted phenol or of a substituted phenol ether is employed here which as substituents carries one or two saturated or unsaturated hydrocarbon radicals which in each case can have up to 4 carbon atoms.

Abstract: A process is disclosed for the baseline separation of the &agr; and &bgr; variants of antithrombin III AT-III. The process involves subjecting a sample comprising AT III to cyclodextrin-modified micellar electrokinetic chromatography (CD-MEKC). The CD-MEKC is performed with a buffer comprising boric acid, an anionic tensid, &bgr;-cyclodextrin, and an aliphatic diamine at a basic pH. The CD-MEKC results in the separation of the AT III into AT III &agr; and ATIII &bgr;. The anionic tensid can be sodium dodecyl sulfate and the aliphatic diamine can be 1, 5-diaminopentane.

Abstract: The invention relates to the removal of viruses from aqueous solutions, as a rule protein solutions, by ultrafiltration. This entails the viruses to be removed being increased in size by incubation with a high molecular weight receptor binding thereto, preferably a specific antibody, so that, on the one hand, the separation effect is improved and, on the other hand, a larger pore diameter which can now be chosen for the filters used also makes it possible for smaller viruses to be separated from larger protein molecules present in protein solutions, and, where appropriate, the filtration rate is increased.

Abstract: Methods for growing and neutralizing or removing circoviruses, in particular porcine circoviruses, which are obtained from an infected cell culture after one or more passages in cultures of porcine, bovine or human cells are described. When the porcine circoviruses grow, a cytopathogenic effect occurs in the cell culture. The circoviruses can be neutralized by treatment with an antibody-containing substrate such as porcine serum or human immunoglobulin or be removed by a pasteurization method. Also described are a vaccine and a diagnostic aid containing inactivated or avirulent circoviruses.

Abstract: The present invention relates to a process for the preparation of a product of blood coagulation factors II, VII, IX and X which is virtually free of virus, the process comprising heating an aqueous liquid containing these factors in the presence of calcium ions and a chelating agent and, optionally, an amino acid, a saccharide or sugar alcohol, antithrombin III and/or heparin. The product can be used for the treatment of blood coagulation disorders.

Abstract: Tissue glue with improved antiadhesive properties The use of a tissue glue which comprises a stabilized fibrinogen preparation which can be stored in the liquid or frozen state and comprises a chaotropic substance, and a thrombin preparation, for reducing or preventing postoperative tissue adhesions is described.

Abstract: The present invention is a multi-pass heat exchanger for use with sterile liquids. The multi-pass heat exchanger includes a tube body and a bonnet, the bonnet being connected to a tubesheet of the tube body. Arranged in the bonnet and dividing the bonnet into at least inlet and outlet chambers is at least one web for directing the liquid conveyed into the bonnet. The web is connected to the bonnet. A gap is provided between the web and the tubesheet, allowing fluid exchange between the bonnet chambers. In this way, a leakage flow, which flushes the gap clear to prevent any type of bacterial deposit or contamination, can flow between the chambers formed by the web. Because the risk of contamination is eliminated, the heat exchanger can be used for the cooling of liquid present in the ultra-pure state, in particular of ultra-pure water.

Abstract: A stabilized protein preparation is described which contains no antithrombin III and is protected against loss of activity during pasteurization by the addition of stabilizers which comprise one or more saccharides as a mixture with more than 0.5 mol/l of one or more amino acids chosen from the group arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts or glutamic acid and its salts. Glycine and/or glutamine can also be additionally added to each of these amino acids. A process for the viral inactivation or viral depletion of a protein preparation of this type which contains the abovementioned stabilizers and is subjected to pasteurization or viral depletion by filtration, centrifugation or treatment with detergents or bactericidal or virucidal agents is also described.

Abstract: A biodegradable, flexible wound covering based on fibrin and a process for its preparation are described, in which a fibrinogen solution is subjected to a single-stage or multistage dialysis, then a flexible fibrin web is formed by action of an aqueous thrombin solution on the fibrinogen solution and this is subsequently subjected to freeze-drying.

Abstract: The production of a thrombin preparation which is obtained from prothrombin which is, after activation to thrombin without the addition of thromboplastin, purified by a hydrophobic interaction chromatography, it being possible subsequently also to inactivate or remove viruses, is described. Before or after the hydrophobic interaction chromatography it is also possible in addition to carry out a cation exchange chromatography. A thrombin preparation which contains as stabilizer a noncovalently binding inhibitor and to which further stabilizers can be added for stabilization in the liquid state is additionally described.

Abstract: A biodegradable, flexible wound covering based on fibrin and a process for its preparation are described, in which a fibrinogen solution is subjected to a single-stage or multistage dialysis, then a flexible fibrin web is formed by action of an aqueous thrombin solution on the fibrinogen solution and this is subsequently subjected to freeze-drying.

Abstract: A fibrinogen solution which is suitable for use in a tissue adhesive and can be stored at temperatures between +4° C. and +25° C. for at least four weeks without loss of its ability to function, in particular without significant change in consistency and coagulation properties, and a process for the preparation thereof.

Abstract: A modified Factor VIII cDNA is described comprising deletion of the B-domain and insertion of at least one truncated Factor IX intron 1 in the Factor VIII cDNA. The modified Factor VIII cDNA may be used for the production of a high yield of Factor VIII in vitro. The modified Factor VIII cDNA may be incorporated into a vector for gene therapy.

Abstract: The invention relates to a process for purifying factor VII and/or activated factor VIIa (F VII/F VIIa) by means of binding to immobilized soluble thromboplastin.

Abstract: The invention relates to the use of complement inhibitors, especially of C1 inactivator or of factors I or H, for the preparation of a pharmaceutical and for the prophylaxis and therapy of chronic inflammatory intestinal disorders, inflammatory skin disorders and purpura.

Abstract: A labeled primer for use in detection of nucleic acid is described, which primer is labeled at the two ends of the oligonucleotide strand with a reporter dye molecule and a quencher molecule, and in which labeled primer, at least one base at the 3′ end is deliberately not complementary to the nucleic acid sequence to be amplified. A process for detecting a nucleic acid sequence using a labeled primer is also described. The process can also be used in amplification processes.

Abstract: A process for separating HIV from a fluid is described, in which the HIV is bound to a C1 esterase inhibitor immobilized on a support material. The process can be carried out both for the preparation of HIV-free blood donations and therapeutically for the reduction of the virus load in the blood by means of a blood lavage under the conditions of an extracorporeal blood circulation. The C1 esterase inhibitor can be bonded to a support material which is customary in affinity chromatography or to the fibers of a filter.

Abstract: A process for the preparation of a concentrate of von Willebrand factor is described, entailing a solution of a complex of this factor with factor VIII:C being optionally pasteurized and treated with an anion exchanger, there being no binding of the von Willebrand factor.